Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

This study has suspended participant recruitment.
Information provided by:
Anosys Identifier:
First received: July 30, 2002
Last updated: June 23, 2005
Last verified: September 2002
The objective is to determine the safety and efficacy of dexosome immunotherapy in patients with Stage IV malignant melanoma

Condition Intervention Phase
Biological: autologous dexosomes loaded with tumor-specific peptides
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Open-Labeled Study of Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

Resource links provided by NLM:

Further study details as provided by Anosys:

Estimated Enrollment: 60
Study Start Date: July 2002

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Patients with Stage IV metastatic melanoma with 0-1 prior treatments for metastatic disease.
  • All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA type A1, A2, or B35.
  • Patients must have adequate organ function and an estimated life expectancy of at least 3 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information Identifier: NCT00042497     History of Changes
Other Study ID Numbers: AN2002-04
Study First Received: July 30, 2002
Last Updated: June 23, 2005

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on May 25, 2017